Primary Cutaneous Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Recipients: A Multicenter European Case Series
Deniz Seçkin(Başkent University), Günther F.L. Hofbauer(University of Zurich), Alexandra Geusau(Medical University of Vienna), Emmanuel Laffitte(Hôpital Beau-Séjour), Jan Nico Bouwes Bavinck(Leiden University Medical Center), Célèste Lebbé(Inserm), Mauro Alaibac(University of Padua), C. Françès(Navarre Institute of Health Research), Stacey Cooper(St Thomas' Hospital), Petra Cetkovská(Charles University), Werner Kempf(University Hospital of Zurich), Charlotte M. Proby(University of Dundee), Sylvie Euvrard(Hospices Civils de Lyon), Catherine Harwood(Queen Mary University of London), Elıf Durukan(Başkent University), Stéphane Barète(Sorbonne Université), V. del Mármol(Université Libre de Bruxelles), A. Tülin Güleç(Başkent University), Carlos Ferrándiz(Universitat Autònoma de Barcelona), Imran Ali(Jamia Millia Islamia), Cato Mørk(Med-Storm Innovation (Norway)), Gillian Murphy(Beaumont Hospital), Jean Kanitakis(Hôpital Lyon Sud)
Cited by 88
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k